Janux Therapeutics Files 2023 Annual Report on Form 10-K

TL;DR

<b>Janux Therapeutics filed its 2023 10-K, detailing its financial position and business activities for the year ended December 31, 2023.</b>

AI Summary

Janux Therapeutics, Inc. (JANX) filed a Annual Report (10-K) with the SEC on March 8, 2024. Janux Therapeutics, Inc. filed its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and headquartered in San Diego, California. The filing covers the period from January 1, 2023, to December 31, 2023. Key financial items referenced include Additional Paid-In Capital, Retained Earnings, and Common Stock. The report also mentions a Merck Agreement and an Underwritten Offering in July 2023.

Why It Matters

For investors and stakeholders tracking Janux Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Janux Therapeutics' financial performance and operational status for the fiscal year 2023, which is crucial for investors to assess the company's health and future prospects. The detailed financial data and disclosures within the report are essential for understanding the company's capital structure, equity, and any significant transactions like the July 2023 underwritten offering.

Risk Assessment

Risk Level: medium — Janux Therapeutics, Inc. shows moderate risk based on this filing. The company is in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, lengthy development cycles, and high R&D costs, as indicated by the SIC code and the nature of the business.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Janux Therapeutics' current financial standing and potential risks in the biopharmaceutical sector.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period end date)
• 2024-03-08 — Filing Date (Date the 10-K was filed)
• 2023-07-31 — Underwritten Offering Date (Date of a significant offering)
• 2022-08-31 — Jefferies Group LLC Date (Date associated with Jefferies Group LLC)

Key Players & Entities

• Janux Therapeutics, Inc. (company) — Filer name
• 2023-12-31 (date) — Fiscal year end
• 2024-03-08 (date) — Filing date
• San Diego, CA (location) — Business address city and state
• Merck Agreement (contract) — Mentioned agreement
• Underwritten Offering (event) — Mentioned transaction
• Jefferies Group LLC (company) — Mentioned underwriter
• 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The pharmaceutical industry is subject to extensive regulation by government authorities, which can impact product development, manufacturing, and marketing.
• Financing Risks [medium — financial]: The company may require additional capital to fund its operations and development programs, and there is no assurance that such financing will be available on favorable terms.
• Research and Development Risks [high — operational]: The success of the company's drug candidates depends on the outcome of extensive research and development efforts, which are inherently uncertain and costly.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-03-08: 10-K Filing Date — Date the annual report was officially submitted to the SEC.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share JANX The Nasdaq
• $11.87 — million base d on the closing price of $11.87 as reported on The Nasdaq Global Market

Filing Documents

• janx-20231231.htm (10-K) — 2634KB
• janx-ex10_5.htm (EX-10.5) — 22KB
• janx-ex10_14.htm (EX-10.14) — 26KB
• janx-ex10_22.htm (EX-10.22) — 53KB
• janx-ex23_1.htm (EX-23.1) — 8KB
• janx-ex31_1.htm (EX-31.1) — 16KB
• janx-ex31_2.htm (EX-31.2) — 15KB
• janx-ex32_1.htm (EX-32.1) — 13KB
• img111646922_0.jpg (GRAPHIC) — 37KB
• img111646922_1.jpg (GRAPHIC) — 249KB
• img111646922_2.jpg (GRAPHIC) — 45KB
• img111646922_3.jpg (GRAPHIC) — 29KB
• img111646922_4.jpg (GRAPHIC) — 16KB
• img111646922_5.jpg (GRAPHIC) — 28KB
• img111646922_6.jpg (GRAPHIC) — 31KB
• img111646922_7.jpg (GRAPHIC) — 100KB
• img111646922_8.jpg (GRAPHIC) — 8KB
• img111646922_9.jpg (GRAPHIC) — 27KB
• img111646922_10.jpg (GRAPHIC) — 26KB
• img111646922_11.jpg (GRAPHIC) — 23KB
• img111646922_12.jpg (GRAPHIC) — 14KB
• img111646922_13.jpg (GRAPHIC) — 21KB
• img111646922_14.jpg (GRAPHIC) — 7KB
• img111646922_15.jpg (GRAPHIC) — 27KB
• img111646922_16.jpg (GRAPHIC) — 110KB
• img111646922_17.jpg (GRAPHIC) — 97KB
• img111646922_18.jpg (GRAPHIC) — 71KB
• img111646922_19.jpg (GRAPHIC) — 111KB
• img111646922_20.jpg (GRAPHIC) — 148KB
• img111646922_21.jpg (GRAPHIC) — 14KB
• img111646922_22.jpg (GRAPHIC) — 19KB
• img111646922_23.jpg (GRAPHIC) — 107KB
• img111646922_24.jpg (GRAPHIC) — 20KB
• img111646922_25.jpg (GRAPHIC) — 66KB
• img111646922_26.jpg (GRAPHIC) — 117KB
• img192204503_0.jpg (GRAPHIC) — 3KB
• 0000950170-24-028659.txt (&nbsp;) — 14597KB
• janx-20231231.xsd (EX-101.SCH) — 1344KB
• janx-20231231_htm.xml (XML) — 2197KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 54 Item 1B. Unresolved Staff Comments 110 Item 1C. Cybersecurity 110 Item 2.

Properties

Properties 111 Item 3.

Legal Proceedings

Legal Proceedings 111 Item 4. Mine Safety Disclosures 112 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 113 Item 6. [Reserved] 114 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 114 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 114 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 124 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 147 Item 9A.

Controls and Procedures

Controls and Procedures 147 Item 9B. Other Information 147 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 147 PART III Item 10. Directors, Executive Officers and Corporate Governance 148 Item 11.

Executive Compensation

Executive Compensation 148 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 148 Item 13. Certain Relationships and Related Transactions, and Director Independence 148 Item 14. Principal Accounting Fees and Services 148 PART IV Item 15. Exhibits and Financial Statement Schedules 149 Item 16. Form 10-K Summary 151

SIGNATURES

SIGNATURES 152 Special Note Regarding Forward-Looking Statements This Annual Report on Form 10-K and the information incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties, many of which are beyond our control. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements as a result of various factors, including those set forth below under the caption "Risk Factors."

Forward-looking statements include, but are not limited to, statements regarding

Forward-looking statements include, but are not limited to, statements regarding: our plans to research, develop and commercialize any product candidates; our ability to obtain and maintain regulatory approval of product candidates arising from our proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platform technologies in any of the indications for which we plan to develop them; our ability to obtain funding for our operations, including funding necessary to commence and complete the clinical trials, conduct additional manufacturing and conduct preclinical studies of any of our product candidates; the success, cost and timing of our research and development activities, including our ongoing and planned preclinical studies and clinical trials; the size of the markets for our product candidates, and our ability to serve those markets; our ability to successfully commercialize our product candidates; the rate and degree of market acceptance of our product candidates; our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators; regulatory developments in the United States and foreign countries; the performance of our third-party service providers, including our CROs, suppliers and manufacturers; the safety, efficacy and market success of competing therapies that are or become available; our ability to attract and retain key scientific and management personnel; our ability to attract and retain collaborators with development, regulatory and commercialization expertise; our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our abi

Business

Item 1. Business. Unless the context otherwise requires, the terms "Janux Therapeutics," "Janux," "we," "us," "our" and similar references in this Annual Report on Form 10-K refer to Janux Therapeutics, Inc. Overview We are an innovative clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Our proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, but overcome liabilities associated with prior generations of TCEs. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors has faced challenges due to the limitations of prior TCE technologies, namely (i) on-target healthy tissue immune activation that contributes to cytokine release syndrome (CRS) and healthy tissue toxicity and (ii) poor pharmacokinetics (PK) leading to short half-life. Our first clinical candidate, JANX007, is a prostate-specific membrane antigen or PSMA-TRACTr and is being investigated in a Phase 1 clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). In February 2024 we announced updated interim clinical data for JANX007 which displayed meaningful PSA drops, and a favorable safety profile, low-grade CRS, and PK, consistent with the TRACTr mechanism-of-action. Our sec

View Full Filing

View this 10-K filing on SEC EDGAR